For Q4 2025, Amicus generated total net product revenue of 185213000, up 24% year over year (20% at constant exchange rates). GAAP net income was 1690000, while non-GAAP net income reached 31630000. Growth was driven by Galafold and Pombiliti + Opfolda demand across global markets.

For Q3 2025, Amicus reported total net product revenue of 169061000, up 17% at constant exchange rates year-over-year, and achieved GAAP net income of 17310000 with diluted EPS of 0.06. Galafold and Pombiliti + Opfolda both contributed to growth, with expanded commercial execution driving results.

Amicus Therapeutics delivered robust second-quarter growth, with total revenue increasing by 18% at constant exchange rates, driven by strong commercial execution for both Galafold and Pombiliti + Opfolda. The company reiterated its 2025 financial guidance, including expectations for GAAP profitability in the second half of 2025, and anticipates exceeding $1 billion in total revenue by 2028.

Amicus Therapeutics delivered significant double-digit revenue growth in Q1 2025, driven by strong underlying patient demand for Galafold and expected acceleration in Pombiliti + Opfolda sales in the second half of the year. The company also in-licensed a Phase 3 program for FSGS, adding a third potential blockbuster to its portfolio, and remains on track for GAAP profitability in H2 2025.

Amicus Therapeutics reported Q4 2024 revenue of $149.7 million, a 30% increase year-over-year. Net income for the quarter was $14.7 million, a significant improvement from a loss of $33.8 million in Q4 2023. Non-GAAP net income was $29.2 million, with a non-GAAP EPS of $0.10. The company continues to expand its commercial presence for Pombiliti + Opfolda and anticipates achieving positive GAAP net income during H2 2025.

Amicus Therapeutics announced strong Q3 2024 results, driven by excellent commercial performance of Galafold and Pombiliti + Opfolda, exceeding expectations and achieving non-GAAP profitability for the full year 2024.

Amicus Therapeutics announced Q2 2024 financial results, reporting a total revenue of $126.7 million, a 34% increase year-over-year. The company achieved non-GAAP profitability in Q2 and H1 2024 and raised its 2024 total revenue growth guidance to 26%-31% at CER.

Amicus Therapeutics announced its Q1 2024 financial results, highlighting a 28% year-over-year increase in total revenue, reaching $110.4 million. The company is raising its full-year 2024 Galafold guidance and is pleased with the strong commercial launch of Pombiliti and Opfolda. Amicus reiterates its full-year non-GAAP profitability projection for 2024.

Amicus Therapeutics announced full-year 2023 financial results, with total revenue of $399.4 million, a 21% increase year-over-year. The company achieved non-GAAP profitability in Q4 and anticipates full-year non-GAAP profitability in 2024.

Amicus Therapeutics had a monumental quarter with the U.S. and U.K. approvals of Pombiliti and Opfolda, the global launches of Pombiliti and Opfolda, and the continued strong growth of Galafold worldwide. The company is on track to achieve all of its annual strategic priorities, including non-GAAP profitability in the fourth quarter.

Amicus Therapeutics announced positive financial results for Q2 2023, with significant progress in Galafold growth and regulatory approvals for Pombiliti and Opfolda in the EU. The company revised its revenue guidance upwards and reduced operating expense guidance, supporting its path to non-GAAP profitability.

Amicus Therapeutics announced a strong start to 2023, with Galafold driving revenue growth and progress made towards the approval and launch of AT-GAA. The company is on track to achieve non-GAAP profitability in the second half of the year.

Amicus Therapeutics announced its full-year 2022 financial results, showcasing a 16% revenue growth at CER to $329 million. The company is projecting Galafold revenue growth of 12-17% at CER in 2023 and anticipates non-GAAP profitability in the second half of 2023. The U.S. FDA pre-approval inspection for AT-GAA is now scheduled, with approval expected in Q3 2023.

Amicus Therapeutics reported strong commercial uptake of Galafold globally and is on track to deliver double-digit operational growth in 2022. The company is making progress towards gaining regulatory approvals of AT-GAA for people living with Pompe disease.

Amicus Therapeutics announced financial results for the quarter ended June 30, 2022. The company is pleased by the continued global uptake of Galafold and continued patient demand, which is driving strong operational growth in-line with 2022 guidance. They are focused on gaining regulatory approvals of AT-GAA for people living with Pompe disease around the world and poised for the anticipated successful launch of AT-GAA.

Amicus Therapeutics reported Q1 2022 financial results, featuring 18.5% growth in Galafold revenue to $78.7 million. The company is advancing regulatory reviews for AT-GAA in Pompe disease and focusing on financial strength.

Amicus Therapeutics announced its full-year 2021 financial results, highlighting Galafold revenue growth of 17% year-over-year to $306 million. The company is focused on advancing Galafold growth and securing AT-GAA approvals for global launches. Strategic portfolio and R&D prioritization are expected to drive ~$400 million in operating expense savings through 2026, with profitability projected in 2023.

Amicus Therapeutics announced its Q3 2021 financial results, featuring an 18% increase in total Galafold revenue compared to Q3 2020. The company is on track to complete the business combination of its gene therapy business with ARYA IV, resulting in the launch of Caritas Therapeutics.

Amicus Therapeutics announced its Q2 2021 financial results, featuring a 24% increase in Galafold revenue compared to Q2 2020. The company also completed the rolling BLA and NDA submissions to the U.S. FDA for AT-GAA in Pompe disease.

Amicus Therapeutics announced its Q1 2021 financial results, with a focus on the commercial growth of Galafold, the regulatory advancements for AT-GAA, and the progress of its gene therapy pipeline. The company is confident in meeting its full-year 2021 revenue guidance.

Amicus Therapeutics announced its full-year 2020 financial results, highlighting the company's resilience and strategic advancements despite the challenges of COVID-19. Galafold revenue increased, and the company is committed to advancing AT-GAA for Pompe disease.

Amicus Therapeutics announced financial results for the third quarter ended September 30, 2020. Galafold 3Q20 Revenue was $67.4 Million and the Company is on-track to achieve Revenue Guidance of $250M-$260M.

Amicus Therapeutics announced financial results for the second quarter ended June 30, 2020, reporting Galafold 2Q2020 Revenue of $62.4 Million and is on track to achieve 2020 Revenue Guidance of $250M-$260M. The Company also summarized recent program updates and reiterated its full-year 2020 guidance.

Amicus Therapeutics announced its Q1 2020 financial results, highlighting the progress in advancing its mission for patients. The company is on track to achieve its 2020 key strategic priorities, including the global Fabry launch and Pompe late-stage development program. The cash runway now extends well into the second half of 2022.

Amicus Therapeutics reported full-year 2019 revenue of $182.2 million, driven by Galafold sales, and anticipates Galafold revenue between $250 million and $260 million for 2020. The company is advancing its Pompe program and gene therapy pipeline, with a cash position expected to fund operations into 2022.